Michael Mark

1.2k total citations
57 papers, 505 citations indexed

About

Michael Mark is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Mark has authored 57 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Michael Mark's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Blood properties and coagulation (8 papers). Michael Mark is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Blood properties and coagulation (8 papers). Michael Mark collaborates with scholars based in Switzerland, Italy and United Kingdom. Michael Mark's co-authors include Walter H. Reinhart, Roland B. Walter, Martin Früh, Patrizia Froesch, Sacha I. Rothschild, Roger von Moos, Dirk Klingbiel, Sabine Schmid, Reto Stocker and Thomas A. Neff and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Michael Mark

54 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Mark Switzerland	13	263	226	123	67	63	57	505
Caroline Archer United Kingdom	11	159 0.6×	244 1.1×	124 1.0×	99 1.5×	69 1.1×	21	522
Yue Teng China	14	180 0.7×	98 0.4×	205 1.7×	107 1.6×	80 1.3×	41	589
Zeki Üstüner Türkiye	11	124 0.5×	219 1.0×	115 0.9×	51 0.8×	26 0.4×	24	562
Xiaojuan Zhang China	11	260 1.0×	259 1.1×	144 1.2×	83 1.2×	24 0.4×	39	515
Nathan D. Seligson United States	13	165 0.6×	213 0.9×	192 1.6×	108 1.6×	29 0.5×	38	532
Wiesław Janusz Kruszewski Poland	13	215 0.8×	234 1.0×	164 1.3×	117 1.7×	47 0.7×	49	672
Yasunori Shikada Japan	14	323 1.2×	269 1.2×	265 2.2×	104 1.6×	51 0.8×	48	796
William Nassib William United States	14	267 1.0×	339 1.5×	227 1.8×	73 1.1×	91 1.4×	44	810
Kuo-Ting Chang Taiwan	12	442 1.7×	328 1.5×	213 1.7×	110 1.6×	71 1.1×	22	749

Countries citing papers authored by Michael Mark

Since Specialization

Citations

This map shows the geographic impact of Michael Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Mark more than expected).

Fields of papers citing papers by Michael Mark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Mark. The network helps show where Michael Mark may publish in the future.

Co-authorship network of co-authors of Michael Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Mark. A scholar is included among the top collaborators of Michael Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Mark. Michael Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lupatsch, Judith E., Michael Mark, Michaela Barbier, et al.. (2025). A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. Swiss Medical Weekly. 155(1). 3777–3777. 1 indexed citations

Schmid, Sabine, Sacha I. Rothschild, Laura Boos, et al.. (2024). Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. JTO Clinical and Research Reports. 5(12). 100735–100735. 2 indexed citations

Johnson, Kristen, Stefanie Hayoz, Alfonso Mora, et al.. (2024). Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison. Supportive Care in Cancer. 32(8). 554–554. 3 indexed citations

Mark, Michael, Patrizia Froesch, Sacha I. Rothschild, et al.. (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European Journal of Cancer. 200. 113600–113600. 3 indexed citations

Mark, Michael, Patrizia Froesch, Sacha I. Rothschild, et al.. (2023). First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.. Journal of Clinical Oncology. 41(16_suppl). 9088–9088.

Johnson, Kevin M., et al.. (2023). 2104P Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison. Annals of Oncology. 34. S1103–S1103. 1 indexed citations

Schmid, Sabine, Sämi Schär, Oliver Gautschi, et al.. (2023). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer. 187. 107427–107427. 9 indexed citations

Mark, Michael, Sylvie Rusakiewicz, Martin Früh, et al.. (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO Open. 7(3). 100446–100446. 5 indexed citations

Addeo, Alfredo, Sacha I. Rothschild, Martina Schneider, et al.. (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer. 172. 154–159. 13 indexed citations

10.

Moiseenko, Fedor, et al.. (2022). 100P Physician perceptions of testing practices in patients with early and advanced stage EGFR mutation-positive (EGFRm) NSCLC: A global survey. Annals of Oncology. 33. S77–S78. 1 indexed citations

11.

Stoffel, Sandro, Roger von Moos, Beat Thürlimann, et al.. (2021). Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. Swiss Medical Weekly. 151(910). w20464–w20464. 5 indexed citations

12.

Froesch, Patrizia, Michael Mark, Sacha I. Rothschild, et al.. (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer. 156. 91–99. 14 indexed citations

13.

Rothschild, Sacha I., Alfred Zippelius, E.I. Eboulet, et al.. (2020). 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial. Annals of Oncology. 31. S803–S804. 11 indexed citations

14.

Ribi, Karin, Beat Thuerlimann, D. Dietrich, et al.. (2020). 1867P Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents: A real-world cross-sectional study from Switzerland (SAKK 95/16). Annals of Oncology. 31. S1065–S1066. 1 indexed citations

15.

Vees, Hansjörg, Francesca Caparrotti, E.I. Eboulet, et al.. (2020). Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). International Journal of Radiation Oncology*Biology*Physics. 107(2). 279–287. 25 indexed citations

16.

Froesch, Patrizia, Michael Mark, Sacha I. Rothschild, et al.. (2020). 557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial. Annals of Oncology. 31. S481–S481. 1 indexed citations

17.

Mark, Michael, Beat Thürlimann, Karin Ribi, et al.. (2019). Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). Journal of bone oncology. 21. 100273–100273. 11 indexed citations

18.

Joerger, Markus, Anastasios Stathis, Yannis Metaxas, et al.. (2019). A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. Investigational New Drugs. 38(4). 1067–1076. 6 indexed citations

19.

Schmid, Sabine, Oliver Gautschi, Sacha I. Rothschild, et al.. (2016). Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Journal of Thoracic Oncology. 12(4). 681–688. 55 indexed citations

20.

Walter, Roland B., et al.. (1999). Influence of nitrovasodilators and endothelin‐1 on rheology of human blood in vitro. British Journal of Pharmacology. 128(3). 744–750. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact